\-\ Texto\\:\\ \ \(0\)\
\-\ exams\\:\\ thyroid\\,\\ cardiovascular\\,\\ lungs\\,\\ and\\ abdominal\\ exams\\ were\\ normal\\.\ \(0\)\
\-\ labs\\:\\ \ \(3\)\
\-\ cbc\\ indicated\\ normocytic\\ anemia\\.\\ \ \(0\)\
\-\ chemistry\\ panel\\ indicated\\ the\\ following\\ abnormalities\\:\ \(0\)\
\-\ glucose\\	\\	serum\\	127\\ \\(h\\)\\ \\	\ \(0\)\
\-\ urea\\ nitrogen\\	serum\\	33\\ \\(h\\)\ \(0\)\
\-\ creatinine\\	serum\\	2\\.2\\ \\(h\\)\\ \ \(0\)\
\-\ pt\\,ptt\\,inr\\:\\ normal\\	\ \(0\)\
\-\ feces\\ occult\\ blood\\ \\â\\€\\“\\ negative\\ on\\ 3\\ samples\\	\ \(0\)\
\-\ helicobacter\\ pylori\\ antibody\\ \\-\\ negative\ \(0\)\
\-\ due\\ to\\ this\\ patient\\â\\€\\™s\\ stage\\ iv\\ metastatic\\ disease\\,\\ surgery\\ was\\ not\\ indicated\\.\\ he\\ was\\ subsequently\\ referred\\ to\\ radiation\\ oncology\\ for\\ palliative\\ treatment\\.\ \(0\)\
\-\ barium\\ esophagram\\ \\(not\\ pictured\\)\ \(0\)\
\-\ conclusion\\:\ \(0\)\
\-\ lower\\ esophageal\\ stricture\\.\\ \\ this\\ is\\ most\\ concerning\\ for\\ malignancy\\ vs\\.\\ possible\\ peptic\\ stricture\\.\\ \\ recommend\\ gi\\ consult\\ for\\ direct\\ visualization\\.\ \(0\)\
\-\ \\ \\ \\ \ \(4545\)\
\-\ ct\\ oncology\\:\\ \ \(0\)\
\-\ impression\\:\ \(2\)\
\-\ findings\\ concerning\\ for\\ distal\\ esophageal\\ carcinoma\\ with\\ regional\\ nodal\\ metastases\\ and\\ possible\\ lung\\ metastases\\.\\ \\ in\\ particular\\,\\ the\\ juxtapleural\\ speculated\\ opacity\\ in\\ the\\ left\\ lower\\ lobe\\ may\\ reflect\\ an\\ area\\ of\\ rounded\\ atelectasis\\,\\ pneumonia\\,\\ or\\ metastatic\\ focus\\.\\ \\ correlate\\ with\\ pending\\ pet\\ scan\\.\ \(0\)\
\-\ pet\\ ct\\:\ \(0\)\
\-\ impression\\:\ \(2\)\
\-\ 1\\.\\ \\ findings\\ consistent\\ with\\ metabolically\\ active\\ mass\\ in\\ the\\ distal\\ esophagus\\ with\\ a\\ maximum\\ suv\\ of\\ 13\\.\\ \\ \ \(0\)\
\-\ 2\\.\\ \\ the\\ left\\ lower\\ lung\\ nodule\\ is\\ metabolically\\ active\\ with\\ a\\ max\\ suv\\ of\\ 5\\.1\\ consistent\\ with\\ metastatic\\ disease\\.\ \(0\)\
\-\ 3\\.\\ \\ multiple\\ nodal\\ metastatic\\ disease\\ involving\\ subcarinal\\ lymph\\ node\\,\\ left\\ infrahilar\\ lymph\\ node\\ and\\ abdominal\\ lymph\\ nodes\\.\ \(0\)\
\-\ 4\\.\\ \\ increased\\ metabolic\\ activity\\ present\\ in\\ the\\ left\\ adrenal\\ with\\ a\\ max\\ suv\\ of\\ 4\\.6\\ consistent\\ with\\ metastatic\\ disease\\.\ \(0\)\
\-\ squamous\\ cell\\ esophageal\\ cancer\ \(0\)\
\-\ peptic\\ stricture\ \(7\)\
\-\ achalasia\ \(51\)\
\-\ esophageal\\ carcinoma\ \(1\)\
\-\ 61\\ y\\.o\\.\\ man\\ presented\\ with\\ dysphagia\\ x\\ 6\\ weeks\\ with\\ solid\\ foods\\.\\ \\ he\\ was\\ able\\ to\\ tolerate\\ some\\ liquid\\ foods\\.\\ \\ he\\ had\\ modified\\ his\\ diet\\ due\\ to\\ these\\ symptoms\\.\\ \\ he\\ had\\ no\\ other\\ symptoms\\.\\ \\ \ \(0\)\
\-\ pmhx\\:\\ coronary\\ artery\\ disease\\ requiring\\ cabg\\ \\â\\€\\“\\ 2\\ vessel\\,\\ htn\\,\\ dm\\ type\\ i\\,\\ hyperlipidemia\\,\\ chronic\\ esophageal\\ reflux\\.\\ no\\ history\\ of\\ smoking\\.\\ \\ \\+30\\ year\\ history\\ of\\ alcohol\\ use\\.\ \(0\)\
\-\ esophageal\\ cancer\\ is\\ a\\ gi\\ malignancy\\ with\\ a\\ predilection\\ for\\ males\\ in\\ the\\ 6th\\-7th\\ decades\\ of\\ life\\.\\ \\ worldwide\\,\\ squamous\\ cell\\ carcinoma\\ is\\ more\\ prevalent\\ than\\ adenocarcinoma\\.\\ \\ however\\,\\ in\\ the\\ u\\.s\\.\\,\\ the\\ increased\\ incidence\\ of\\ adenocarcinoma\\ in\\ white\\ males\\ has\\ made\\ it\\ the\\ most\\ common\\ esophageal\\ malignancy\\.\\ \\ squamous\\ cell\\ carcinoma\\ remains\\ the\\ most\\ common\\ type\\ in\\ african\\-american\\ males\\.\\ \\ \ \(0\)\
\-\ two\\ primary\\ risk\\ factors\\ for\\ squamous\\ cell\\ carcinoma\\ of\\ the\\ esophagus\\ have\\ been\\ identified\\ in\\ developed\\ countries\\:\\ alcohol\\ consumption\\ and\\ cigarette\\ smoking\\.\\ \\ presumably\\,\\ it\\ is\\ for\\ this\\ reason\\ that\\ the\\ most\\ common\\ location\\ for\\ squamous\\ lesions\\ are\\ in\\ the\\ proximal\\ and\\ mid\\-portions\\ of\\ the\\ esophagus\\.\\ \\ in\\ asian\\ countries\\,\\ n\\-nitroso\\ compounds\\ found\\ in\\ smoked\\ foods\\ have\\ also\\ been\\ implicated\\ in\\ squamous\\ cell\\ lesions\\.\ \(0\)\
\-\ patients\\ usually\\ have\\ no\\ symptoms\\ until\\ late\\ in\\ the\\ course\\ of\\ disease\\ due\\ to\\ the\\ compliance\\ of\\ the\\ esophagus\\.\\ \\ the\\ first\\ symptom\\ is\\ usually\\ dysphagia\\ or\\ odynophagia\\ to\\ solid\\ foods\\.\\ \\ this\\ means\\ the\\ disease\\ is\\ often\\ quite\\ advanced\\ at\\ diagnosis\\ and\\ therefore\\ carries\\ a\\ very\\ poor\\ prognosis\\.\\ \\ \\ \ \(0\)\
\-\ esophageal\\ cancer\\ is\\ usually\\ suspected\\ after\\ an\\ abnormal\\ barium\\ esophagram\\ conducted\\ for\\ dysphagia\\.\\ \\ the\\ addition\\ of\\ ct\\ allows\\ for\\ further\\ assessment\\ of\\ metastatic\\ disease\\ and\\ regional\\ invasion\\.\\ \\ endoscopic\\ ultrasound\\ \\(eus\\)\\ is\\ often\\ obtained\\ when\\ no\\ evidence\\ of\\ metastatic\\ disease\\ exists\\ to\\ increase\\ the\\ accuracy\\ of\\ locoregional\\ metastases\\ and\\ staging\\ prior\\ to\\ surgery\\.\\ \\ fdg\\-pet\\ or\\ fdg\\-pet\\ ct\\ may\\ also\\ be\\ used\\ when\\ questions\\ exist\\ regarding\\ distant\\ metastasis\\.\\ \\ \\ it\\ has\\ been\\ found\\ in\\ previous\\ studies\\ that\\ pet\\ is\\ more\\ accurate\\ in\\ detecting\\ stage\\ iv\\ disease\\ than\\ ct\\ alone\\ or\\ in\\ combination\\ with\\ eus\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ esophageal\\:\\ 0\\.05038814950502362\ \(0\)\
\-\ squamous\\:\\ 0\\.040329158544085496\ \(0\)\
\-\ foods\\:\\ 0\\.040196585636687855\ \(0\)\
\-\ suv\\:\\ 0\\.028317103431511535\ \(0\)\
\-\ eus\\:\\ 0\\.02611694933571239\ \(0\)\
\-\ fdg\\-pet\\:\\ 0\\.02611694933571239\ \(0\)\
\-\ metabolically\\:\\ 0\\.024813203007390316\ \(0\)\
\-\ metastatic\\:\\ 0\\.024208626728798446\ \(0\)\
\-\ max\\:\\ 0\\.023888180266387806\ \(0\)\
\-\ countries\\:\\ 0\\.023888180266387806\ \(0\)\
\-\ esophagus\\:\\ 0\\.023855774598494646\ \(0\)\
\-\ males\\:\\ 0\\.023747740156861118\ \(0\)\
\-\ disease\\:\\ 0\\.022455587479352154\ \(0\)\
\-\ stricture\\:\\ 0\\.022096842054835558\ \(0\)\
\-\ h\\:\\ 0\\.021694679953843353\ \(0\)\
\-\ pet\\:\\ 0\\.021630796223537786\ \(0\)\
\-\ dysphagia\\:\\ 0\\.020071823507117247\ \(0\)\
\-\ \\:\\:\\ 0\\.019988782919449062\ \(0\)\
\-\ serum\\:\\ 0\\.019891497789730008\ \(0\)\
\-\ esophagram\\:\\ 0\\.019638161488309606\ \(0\)\
\-\ carcinoma\\:\\ 0\\.019468871945465163\ \(0\)\
\-\ peptic\\:\\ 0\\.0185562571904922\ \(0\)\
\-\ cell\\:\\ 0\\.018554989642937992\ \(0\)\
\-\ nodal\\:\\ 0\\.018406675146650103\ \(0\)\
\-\ indicated\\:\\ 0\\.017833719991397476\ \(0\)\
\-\ metastases\\:\\ 0\\.017608034324966163\ \(0\)\
\-\ oncology\\:\\ 0\\.01751840062372998\ \(0\)\
\-\ regional\\:\\ 0\\.017409392418985023\ \(0\)\
\-\ lymph\\:\\ 0\\.016637664351823057\ \(0\)\
\-\ malignancy\\:\\ 0\\.015926477545666475\ \(0\)\
\-\ exams\\:\\ 0\\.015519403142772423\ \(0\)\
\-\ he\\:\\ 0\\.015332394482527456\ \(0\)\
\-\ impression\\:\\ 0\\.014684961999733565\ \(0\)\
\-\ concerning\\:\\ 0\\.014420530815691855\ \(0\)\
\-\ juxtapleural\\:\\ 0\\.014172859202518486\ \(0\)\
\-\ \\+30\\:\\ 0\\.014172859202518486\ \(0\)\
\-\ 6th\\-7th\\:\\ 0\\.014172859202518486\ \(0\)\
\-\ mid\\-portions\\:\\ 0\\.014172859202518486\ \(0\)\
\-\ n\\-nitroso\\:\\ 0\\.014172859202518486\ \(0\)\
\-\ smoking\\:\\ 0\\.013876877021338371\ \(0\)\
\-\ alcohol\\:\\ 0\\.013841347001445814\ \(0\)\
\-\ cancer\\:\\ 0\\.013549028606260926\ \(0\)\
\-\ barium\\:\\ 0\\.013320545303873286\ \(0\)\
\-\ infrahilar\\:\\ 0\\.013058474667856194\ \(0\)\
\-\ u\\.s\\.\\:\\ 0\\.013058474667856194\ \(0\)\
\-\ locoregional\\:\\ 0\\.013058474667856194\ \(0\)\
\-\ most\\:\\ 0\\.01268704271207766\ \(0\)\
\-\ node\\:\\ 0\\.012573130693016297\ \(0\)\
\-\ usually\\:\\ 0\\.012515731127974723\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.01236561133244533\ \(0\)\
\-\ gi\\:\\ 0\\.012343359104649272\ \(0\)\
\-\ normocytic\\:\\ 0\\.011944090133193903\ \(0\)\
\-\ compounds\\:\\ 0\\.011944090133193903\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.011869949982518453\ \(0\)\
\-\ for\\:\\ 0\\.011721995958886094\ \(0\)\
\-\ stage\\:\\ 0\\.011720367938676356\ \(0\)\
\-\ urea\\:\\ 0\\.011585338442978132\ \(0\)\
\-\ nitrogen\\:\\ 0\\.011585338442978132\ \(0\)\
\-\ feces\\:\\ 0\\.011585338442978132\ \(0\)\
\-\ helicobacter\\:\\ 0\\.011585338442978132\ \(0\)\
\-\ in\\:\\ 0\\.011517287640489282\ \(0\)\
\-\ 127\\:\\ 0\\.011292216969032867\ \(0\)\
\-\ pictured\\:\\ 0\\.011292216969032867\ \(0\)\
\-\ speculated\\:\\ 0\\.011292216969032867\ \(0\)\
\-\ been\\:\\ 0\\.011212837087446904\ \(0\)\
\-\ samples\\:\\ 0\\.011044386294069428\ \(0\)\
\-\ due\\:\\ 0\\.010998121316492797\ \(0\)\
\-\ solid\\:\\ 0\\.010959313995197362\ \(0\)\
\-\ worldwide\\:\\ 0\\.010829705598531612\ \(0\)\
\-\ compliance\\:\\ 0\\.010829705598531612\ \(0\)\
\-\ common\\:\\ 0\\.010785854720046933\ \(0\)\
\-\ chemistry\\:\\ 0\\.01064034380487183\ \(0\)\
\-\ 4\\.6\\:\\ 0\\.01064034380487183\ \(0\)\
\-\ consumption\\:\\ 0\\.01064034380487183\ \(0\)\
\-\ active\\:\\ 0\\.010490542890819552\ \(0\)\
\-\ cigarette\\:\\ 0\\.010470953908315839\ \(0\)\
\-\ smoked\\:\\ 0\\.010470953908315839\ \(0\)\
\-\ implicated\\:\\ 0\\.010470953908315839\ \(0\)\
\-\ prevalent\\:\\ 0\\.010317722107987343\ \(0\)\
\-\ symptoms\\:\\ 0\\.010271659856421894\ \(0\)\
\-\ reflect\\:\\ 0\\.010177832434370575\ \(0\)\
\-\ subcarinal\\:\\ 0\\.010177832434370575\ \(0\)\
\-\ consistent\\:\\ 0\\.010105940203365932\ \(0\)\
\-\ pylori\\:\\ 0\\.010049146409171964\ \(0\)\
\-\ questions\\:\\ 0\\.010049146409171964\ \(0\)\
\-\ iv\\:\\ 0\\.01002708983106461\ \(0\)\
\-\ conclusion\\:\\ 0\\.009930001759407137\ \(0\)\
\-\ exists\\:\\ 0\\.009930001759407137\ \(0\)\
\-\ carries\\:\\ 0\\.009819080744154803\ \(0\)\
\-\ ptt\\:\\ 0\\.009715321063869319\ \(0\)\
\-\ 5\\.1\\:\\ 0\\.009715321063869319\ \(0\)\
\-\ odynophagia\\:\\ 0\\.009715321063869319\ \(0\)\
\-\ liquid\\:\\ 0\\.009617853826222319\ \(0\)\
\-\ ct\\:\\ 0\\.009608550268424781\ \(0\)\
\-\ tolerate\\:\\ 0\\.009439034477170512\ \(0\)\
\-\ exist\\:\\ 0\\.009439034477170512\ \(0\)\
\-\ lower\\:\\ 0\\.009269431202719596\ \(0\)\
\-\ it\\:\\ 0\\.009264542047586899\ \(0\)\
\-\ type\\:\\ 0\\.00926245732587431\ \(0\)\
\-\ possible\\:\\ 0\\.009253962118598302\ \(0\)\
\-\ modified\\:\\ 0\\.009203337573325051\ \(0\)\
\-\ cabg\\:\\ 0\\.009203337573325051\ \(0\)\
\-\ presumably\\:\\ 0\\.009203337573325051\ \(0\)\
\-\ accuracy\\:\\ 0\\.009203337573325051\ \(0\)\
\-\ antibody\\:\\ 0\\.009131871717101846\ \(0\)\
\-\ recommend\\:\\ 0\\.009131871717101846\ \(0\)\
\-\ 2\\.2\\:\\ 0\\.009063447899708282\ \(0\)\
\-\ predilection\\:\\ 0\\.009063447899708282\ \(0\)\
\-\ conducted\\:\\ 0\\.009063447899708282\ \(0\)\
\-\ detecting\\:\\ 0\\.009063447899708282\ \(0\)\
\-\ is\\:\\ 0\\.00904004466856472\ \(0\)\
\-\ asian\\:\\ 0\\.00893476187450967\ \(0\)\
\-\ accurate\\:\\ 0\\.00893476187450967\ \(0\)\
\-\ have\\:\\ 0\\.008924942500153176\ \(0\)\
\-\ african\\-american\\:\\ 0\\.008874086106048503\ \(0\)\
\-\ decades\\:\\ 0\\.008815617224744846\ \(0\)\
\-\ often\\:\\ 0\\.008766795975947435\ \(0\)\
\-\ achalasia\\:\\ 0\\.00875920031186499\ \(0\)\
\-\ dm\\:\\ 0\\.008704696209492511\ \(0\)\
\-\ means\\:\\ 0\\.008704696209492511\ \(0\)\
\-\ found\\:\\ 0\\.008659246348720619\ \(0\)\
\-\ reason\\:\\ 0\\.008651979452542367\ \(0\)\
\-\ inr\\:\\ 0\\.008600936529207027\ \(0\)\
\-\ correlate\\:\\ 0\\.008551464409164015\ \(0\)\
\-\ hyperlipidemia\\:\\ 0\\.008503469291560027\ \(0\)\
\-\ allows\\:\\ 0\\.008456865534529075\ \(0\)\
\-\ diet\\:\\ 0\\.008411574735547248\ \(0\)\
\-\ palliative\\:\\ 0\\.00836752493781716\ \(0\)\
\-\ occult\\:\\ 0\\.008282888710348636\ \(0\)\
\-\ quite\\:\\ 0\\.008282888710348636\ \(0\)\
\-\ \\,\\:\\ 0\\.00826927852866312\ \(0\)\
\-\ negative\\:\\ 0\\.008206174152330785\ \(0\)\
\-\ consult\\:\\ 0\\.00816374406058381\ \(0\)\
\-\ maximum\\:\\ 0\\.00816374406058381\ \(0\)\
\-\ pmhx\\:\\ 0\\.008125913678895395\ \(0\)\
\-\ panel\\:\\ 0\\.00808895303866276\ \(0\)\
\-\ 61\\:\\ 0\\.00808895303866276\ \(0\)\
\-\ endoscopic\\:\\ 0\\.00808895303866276\ \(0\)\
\-\ regarding\\:\\ 0\\.008052823045331477\ \(0\)\
\-\ distant\\:\\ 0\\.008017487182439555\ \(0\)\
\-\ lung\\:\\ 0\\.007958710997552238\ \(0\)\
\-\ staging\\:\\ 0\\.007915913385620373\ \(0\)\
\-\ when\\:\\ 0\\.007869232275292622\ \(0\)\
\-\ creatinine\\:\\ 0\\.00782037733984738\ \(0\)\
\-\ symptom\\:\\ 0\\.007789753232177454\ \(0\)\
\-\ coronary\\:\\ 0\\.007730201348446989\ \(0\)\
\-\ cardiovascular\\:\\ 0\\.007701232690082554\ \(0\)\
\-\ requiring\\:\\ 0\\.007590311674830222\ \(0\)\
\-\ htn\\:\\ 0\\.007563737234394191\ \(0\)\
\-\ distal\\:\\ 0\\.0074703491605981566\ \(0\)\
\-\ alone\\:\\ 0\\.007437079874501724\ \(0\)\
\-\ assessment\\:\\ 0\\.007389084756897735\ \(0\)\
\-\ particular\\:\\ 0\\.007365614018278519\ \(0\)\
\-\ lesions\\:\\ 0\\.007355500020398546\ \(0\)\
\-\ glucose\\:\\ 0\\.0073424809998667824\ \(0\)\
\-\ visualization\\:\\ 0\\.007253140403154868\ \(0\)\
\-\ than\\:\\ 0\\.007199514002952649\ \(0\)\
\-\ remains\\:\\ 0\\.007148023426848033\ \(0\)\
\-\ late\\:\\ 0\\.007148023426848033\ \(0\)\
\-\ 33\\:\\ 0\\.007127800304328965\ \(0\)\
\-\ advanced\\:\\ 0\\.007030333066681964\ \(0\)\
\-\ adrenal\\:\\ 0\\.006956402016453953\ \(0\)\
\-\ combination\\:\\ 0\\.006920673500722907\ \(0\)\
\-\ more\\:\\ 0\\.0068719495476275445\ \(0\)\
\-\ abdominal\\:\\ 0\\.006867907518077541\ \(0\)\
\-\ anemia\\:\\ 0\\.006834678830383701\ \(0\)\
\-\ metabolic\\:\\ 0\\.006785206710340689\ \(0\)\
\-\ rounded\\:\\ 0\\.006769048614113194\ \(0\)\
\-\ increased\\:\\ 0\\.00672181601864841\ \(0\)\
\-\ surgery\\:\\ 0\\.006672022714984807\ \(0\)\
\-\ invasion\\:\\ 0\\.006615816813784698\ \(0\)\
\-\ atelectasis\\:\\ 0\\.0066012672389938335\ \(0\)\
\-\ vessel\\:\\ 0\\.006544350957561492\ \(0\)\
\-\ prognosis\\:\\ 0\\.006516631011525309\ \(0\)\
\-\ direct\\:\\ 0\\.006489380917773261\ \(0\)\
\-\ therefore\\:\\ 0\\.006489380917773261\ \(0\)\
\-\ able\\:\\ 0\\.00647592714016793\ \(0\)\
\-\ or\\:\\ 0\\.006440660765039919\ \(0\)\
\-\ opacity\\:\\ 0\\.006423210383217783\ \(0\)\
\-\ reflux\\:\\ 0\\.006347241114969318\ \(0\)\
\-\ incidence\\:\\ 0\\.0062985186881279525\ \(0\)\
\-\ subsequently\\:\\ 0\\.006228096465204492\ \(0\)\
\-\ 13\\:\\ 0\\.006205291585796201\ \(0\)\
\-\ nodes\\:\\ 0\\.006205291585796201\ \(0\)\
\-\ poor\\:\\ 0\\.006182805666222665\ \(0\)\
\-\ this\\:\\ 0\\.0061809467094156465\ \(0\)\
\-\ focus\\:\\ 0\\.006171679552324636\ \(0\)\
\-\ factors\\:\\ 0\\.006171679552324636\ \(0\)\
\-\ left\\:\\ 0\\.006148586940661831\ \(0\)\
\-\ cbc\\:\\ 0\\.006138755868492577\ \(0\)\
\-\ until\\:\\ 0\\.006033638892185742\ \(0\)\
\-\ may\\:\\ 0\\.006026779321215832\ \(0\)\
\-\ life\\:\\ 0\\.005993443872562884\ \(0\)\
\-\ pending\\:\\ 0\\.005944573330465826\ \(0\)\
\-\ had\\:\\ 0\\.005928777553828644\ \(0\)\
\-\ suspected\\:\\ 0\\.005915948532019672\ \(0\)\
\-\ findings\\:\\ 0\\.005848350275851961\ \(0\)\
\-\ addition\\:\\ 0\\.005824053976006893\ \(0\)\
\-\ \\(\\:\\ 0\\.005806766288133927\ \(0\)\
\-\ increase\\:\\ 0\\.005762716731691176\ \(0\)\
\-\ \\)\\:\\ 0\\.005735833537888304\ \(0\)\
\-\ pneumonia\\:\\ 0\\.0056789625325217195\ \(0\)\
\-\ i\\:\\ 0\\.0056789625325217195\ \(0\)\
\-\ nodule\\:\\ 0\\.005662722828363354\ \(0\)\
\-\ thyroid\\:\\ 0\\.005630727403415934\ \(0\)\
\-\ no\\:\\ 0\\.005533402898416733\ \(0\)\
\-\ to\\:\\ 0\\.005492837407626833\ \(0\)\
\-\ made\\:\\ 0\\.005472463620757971\ \(0\)\
\-\ use\\:\\ 0\\.0054299664228992005\ \(0\)\
\-\ also\\:\\ 0\\.005416783259389554\ \(0\)\
\-\ vs\\:\\ 0\\.005409131785210286\ \(0\)\
\-\ 4\\.\\:\\ 0\\.005409131785210286\ \(0\)\
\-\ previous\\:\\ 0\\.005334968165069608\ \(0\)\
\-\ developed\\:\\ 0\\.005289494348608865\ \(0\)\
\-\ used\\:\\ 0\\.005270392535286112\ \(0\)\
\-\ lungs\\:\\ 0\\.0052022324726371\ \(0\)\
\-\ referred\\:\\ 0\\.005184134153465661\ \(0\)\
\-\ course\\:\\ 0\\.005184134153465661\ \(0\)\
\-\ has\\:\\ 0\\.00515980697908128\ \(0\)\
\-\ activity\\:\\ 0\\.00515441580189958\ \(0\)\
\-\ metastasis\\:\\ 0\\.0051426805889066346\ \(0\)\
\-\ studies\\:\\ 0\\.005131030414435948\ \(0\)\
\-\ pt\\:\\ 0\\.005107980312914393\ \(0\)\
\-\ abnormalities\\:\\ 0\\.005046245372505171\ \(0\)\
\-\ very\\:\\ 0\\.004986793598805674\ \(0\)\
\-\ risk\\:\\ 0\\.004976216474853837\ \(0\)\
\-\ identified\\:\\ 0\\.004909110998691835\ \(0\)\
\-\ the\\:\\ 0\\.0048898460827649\ \(0\)\
\-\ obtained\\:\\ 0\\.004884029100874343\ \(0\)\
\-\ involving\\:\\ 0\\.004820590456596935\ \(0\)\
\-\ location\\:\\ 0\\.004792134544861565\ \(0\)\
\-\ labs\\:\\ 0\\.004778093258738164\ \(0\)\
\-\ was\\:\\ 0\\.004766611843474374\ \(0\)\
\-\ that\\:\\ 0\\.0047459187413466985\ \(0\)\
\-\ 3\\.\\:\\ 0\\.004700762398940076\ \(0\)\
\-\ first\\:\\ 0\\.004610101985186257\ \(0\)\
\-\ white\\:\\ 0\\.004556437641016106\ \(0\)\
\-\ x\\:\\ 0\\.004532260989304626\ \(0\)\
\-\ radiation\\:\\ 0\\.004508442523412116\ \(0\)\
\-\ 2\\.\\:\\ 0\\.004368881256913599\ \(0\)\
\-\ further\\:\\ 0\\.004368881256913599\ \(0\)\
\-\ area\\:\\ 0\\.004343788173849304\ \(0\)\
\-\ normal\\:\\ 0\\.00430743554533473\ \(0\)\
\-\ 1\\.\\:\\ 0\\.004291300910446304\ \(0\)\
\-\ some\\:\\ 0\\.004171910375991574\ \(0\)\
\-\ proximal\\:\\ 0\\.004124667494705812\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.004106152314542534\ \(0\)\
\-\ 6\\:\\ 0\\.004103087076165393\ \(0\)\
\-\ artery\\:\\ 0\\.004090884231685207\ \(0\)\
\-\ ultrasound\\:\\ 0\\.004075759782968333\ \(0\)\
\-\ primary\\:\\ 0\\.004069749618803371\ \(0\)\
\-\ not\\:\\ 0\\.003970478044186287\ \(0\)\
\-\ y\\.o\\:\\ 0\\.003965240245316238\ \(0\)\
\-\ his\\:\\ 0\\.003959628661811787\ \(0\)\
\-\ s\\:\\ 0\\.003940140943914127\ \(0\)\
\-\ two\\:\\ 0\\.003934616137646311\ \(0\)\
\-\ abnormal\\:\\ 0\\.003918154727194392\ \(0\)\
\-\ following\\:\\ 0\\.0038991603808700135\ \(0\)\
\-\ weeks\\:\\ 0\\.0038991603808700135\ \(0\)\
\-\ chronic\\:\\ 0\\.0038697582522620576\ \(0\)\
\-\ scan\\:\\ 0\\.0038460955955514123\ \(0\)\
\-\ a\\:\\ 0\\.0038257215609511378\ \(0\)\
\-\ however\\:\\ 0\\.0038253505716994702\ \(0\)\
\-\ an\\:\\ 0\\.0037995654800152085\ \(0\)\
\-\ history\\:\\ 0\\.003794902050505091\ \(0\)\
\-\ blood\\:\\ 0\\.003749857029757716\ \(0\)\
\-\ presented\\:\\ 0\\.00374494796627397\ \(0\)\
\-\ lobe\\:\\ 0\\.0036966645465008586\ \(0\)\
\-\ evidence\\:\\ 0\\.0036019977224547874\ \(0\)\
\-\ these\\:\\ 0\\.003575313009578521\ \(0\)\
\-\ patients\\:\\ 0\\.0035555861726141893\ \(0\)\
\-\ prior\\:\\ 0\\.003527512495502192\ \(0\)\
\-\ man\\:\\ 0\\.0032490865644533747\ \(0\)\
\-\ 3\\:\\ 0\\.0032170024545121216\ \(0\)\
\-\ other\\:\\ 0\\.0031666214609364124\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0031546934578463343\ \(0\)\
\-\ were\\:\\ 0\\.0031194314094693267\ \(0\)\
\-\ present\\:\\ 0\\.003102907964520387\ \(0\)\
\-\ of\\:\\ 0\\.0029968823356395736\ \(0\)\
\-\ 2\\:\\ 0\\.002958367357733997\ \(0\)\
\-\ \\-\\:\\ 0\\.0029449010590166616\ \(0\)\
\-\ multiple\\:\\ 0\\.002893578783728728\ \(0\)\
\-\ after\\:\\ 0\\.0028424456633588465\ \(0\)\
\-\ treatment\\:\\ 0\\.0027807346617377605\ \(0\)\
\-\ and\\:\\ 0\\.002315228369546218\ \(0\)\
\-\ with\\:\\ 0\\.002257315294338709\ \(0\)\
\-\ \\.\\:\\ 0\\.0021687819480693867\ \(0\)\
\-\ be\\:\\ 0\\.00211857994106741\ \(0\)\
\-\ mass\\:\\ 0\\.001910709014385152\ \(0\)\
\-\ are\\:\\ 0\\.0018727875764141507\ \(0\)\
\-\ at\\:\\ 0\\.0018613555511762588\ \(0\)\
\-\ year\\:\\ 0\\.0015371467351654577\ \(0\)\
\-\ patient\\:\\ 0\\.001377157445203196\ \(0\)\
\-\ on\\:\\ 0\\.0011638119169862188\ \(0\)\
